485-72-3Relevant articles and documents
Metabolic studies of four soy isoflavones in rats by HPLC-HR-MS
Li, Ying-Fei,Ren, Qiang,Jin, Ying,Wu, Cai-Sheng,Wang, Cai-Hong,Jia, Zhi-Xin,Zhang, Jin-Lan
, p. 497 - 510 (2014)
In this paper, the metabolites of four soy isoflavones, daidzein, daidzin, genistein, and genistin, on perfused rat intestine-liver model were investigated by high-performance liquid chromatography coupled with high-resolution mass spectrometer/tandem mass spectrometer. Totally 16 metabolites were detected and identified based on accurate mass, fragmentation patterns, and multiple-stage mass data (MSn). The metabolic site of dadzein-7-methyl ether (D-7-M) was further confirmed by nuclear magnetic resonance. Methylation, glucuronide conjugation, and sulfate conjugation were the primary metabolic processes. Among them, six metabolites, daidzin-4′,7-diglucoside, genistein-4′- glucoside, D-7-M, dadzein-4′,7-dimethyl ether, genistein-4′-methyl ether, and genistein-7-methyl ether were detected in rats for the first time and not reported in humans. The metabolic pathways of daidzein, daidzin genistein, and genistin in rats were postulated. The biological effects of these metabolites are worthy of further investigation.
INDUCIBLY-FORMED ISOFLAVONOIDS FROM LEAVES OF SOYBEAN
Ingham, John L.,Keen, Noel T.,Mulheirn, Lawrence J.,Lyne, Robert L.
, p. 795 - 798 (1981)
Isoformononetin, glyceollins I, II and III, and 2-isopentenyl-3,6α,9-trihydroxypterocarpan (glyceocarpin) accumulated in soybean (Glycine max) leaves after treatment with aqueous sodium iodoacetate or a cell suspension of the bacterium, Pseudomonas pisi.These compounds were also accompanied by two previously unreported pterocarpans, glycerofuran and its 9-O-methyl derivative.Glyceocarpin is described for the first time as a plant product.Key Word Index- Glycine max; Leguminosae; soybean; Pseudomonas pisi; isoflavonoids; pterocarpans; isoflavone; phytoalexins; antibacterial activity.
Identification of ortho catechol-containing isoflavone as a privileged scaffold that directly prevents the aggregation of both amyloid β plaques and tau-mediated neurofibrillary tangles and its in vivo evaluation
Do, Ji Min,Gee, Min Sung,Inn, Kyung-Soo,Kim, Jong-Ho,Kim, Nam Kwon,Kim, Nam-Jung,Lee, Hyun Woo,Lee, Jong Kil,Seo, Min-Duk,Seong, Ji Hye,Son, Seung Hwan,Yoo, Hyung-Seok,Yoo, Ji-Na
, (2021/07/01)
In this study, polyhydroxyisoflavones that directly prevent the aggregation of both amyloid β (Aβ) and tau were expediently synthesized via divergent Pd(0)-catalyzed Suzuki-Miyaura coupling and then biologically evaluated. By preliminary structure–activity relationship studies using thioflavin T (ThT) assays, an ortho-catechol containing isoflavone scaffold was proven to be crucial for preventing both Aβ aggregation and tau-mediated neurofibrillary tangle formation. Additional TEM experiment confirmed that ortho-catechol containing isoflavone 4d significantly prevented the aggregation of both Aβ and tau. To investigate the mode of action (MOA) of 4d, which possesses an ortho-catechol moiety, 1H-15N HSQC NMR analysis was thoroughly performed and the result indicated that 4d could directly inhibit both the formation of Aβ42 fibrils and the formation of tau-derived neurofibrils, probably through the catechol-mediated nucleation of tau. Finally, 4d was demonstrated to alleviate cognitive impairment and pathologies related to Alzheimer's disease in a 5XFAD transgenic mouse model.
Novel isoflavone derivative, preparation method therefor and medicinal use of novel isoflavone derivative
-
Paragraph 0066-0067; 0071-0073, (2018/07/30)
The invention relates to the field of pharmaceutical chemistry, relates to an isoflavone derivative, a preparation method therefor and medicinal use of the novel isoflavone derivative and particularlyrelates to isoflavone derivatives represented by a general formula (I) shown in the description, preparation methods therefor, pharmaceutical compositions containing these compounds and medicinal useof the isoflavone derivatives and the pharmaceutical compositions, particularly use of drugs for preventing or treating hyperlipidemia, type II diabetes, atherosclerosis and non-alcoholic fatty hepatitis.